NCT03683524View on ClinicalTrials.gov

EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS CARRYING ARCHIVED MULTIDRUG RESISTANCE MUTATIONS

PHASE4CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

November 19, 2018

Primary Completion Date

August 10, 2021

Study Completion Date

August 10, 2021

Conditions
HIV-1 Infection
Interventions
DRUG

Dolutegravir (DTG) plus Darunavir/cobicistat (DRV/cobi).

bitherapy based on DTG (50 mg QD) plus DRV/cobi (800/150 mg QD)

DRUG

Current ART

To continue with their current ART

Trial Locations (1)

08916

Hospital Germans Trias I Pujol, Badalona

Sponsors

Collaborators (1)

ViiV Healthcare
All Listed Sponsors
collaborator

ViiV Healthcare

INDUSTRY

lead

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

OTHER